Cleveland Clinic Study Finds 45% of Patients Maintain Weight Loss One Year After Halting GLP-1 Medications

New Cleveland Clinic research shows 45% of patients maintain weight loss a year after stopping GLP-1 drugs like Wegovy and Mounjaro through alternative care.

By: AXL Media

Published: Mar 14, 2026, 6:20 AM EDT

Source: Information for this report was sourced from Cleveland Clinic

A Departure From Clinical Trial Weight Regain Patterns

The traditional narrative surrounding GLP-1 receptor agonists suggests that patients who cease treatment inevitably face a sharp rebound in body weight, yet new real-world data challenges this assumption. According to a study led by Dr. Hamlet Gasoyan of the Cleveland Clinic, nearly half of the patients who stopped taking medications like semaglutide or tirzepatide managed to maintain their weight or continue losing it a year later. This findings provide a critical counterpoint to randomized controlled trials, which previously indicated that patients typically regain more than half of their lost weight within a 12 month window following discontinuation.

Divergent Outcomes for Obesity and Diabetes Management

The retrospective cohort study, which tracked 7,938 adults across Ohio and Florida, highlighted distinct physiological responses based on the initial reason for the prescription. Patients specifically treated for obesity lost an average of 8.4% of their body weight during active treatment and saw a negligible average regain of just 0.5% a year after stopping the injections. Conversely, those utilizing the drugs for type 2 diabetes lost 4.4% during the treatment phase and actually continued to lose an additional 1.3% of their body weight in the year following their last dose, suggesting a sustained metabolic shift or higher adherence to secondary management strategies.

The Resilience of Patient Weight Loss Journeys

Success in long-term weight management appears to stem from a refusal to abandon the treatment path once the primary medication is no longer an option. Dr. Gasoyan noted that the data reflects a persistent commitment among patients, many of whom transition into a secondary phase of care rather than stopping all interventions entirely. This proactive approach by patients and clinicians helps bridge the gap between pharmaceutical assistance and long-term maintenance, ensuring that the initial progress made during the injectable phase is not discarded due to a change in prescription status.